Fresh financial threat is circling the pharmaceutical industry which is facing tremendous political pressure for producing generic biotechnology. As of now the market for biotech drugs is around $60bn and the Access to Life-Saving Medicines Act has been introduced for the purpose of setting up a clear regulatory pathway for copying some of industry’s valuable biotech drugs. Besides this there is added pressure from WHO which is conducting a meeting next month for tackling the issue of whether the biotech drugs which were not the same copy of branded drugs could still carry the same clinical name. Mike Ward, analyst, Nomura Code Securities says: The scene we have now is that the [pharmaceutical] companies want to hang on to what they’ve got. There are no set guidelines on either side of the Atlantic as to how you get these generics to the market. But the market is huge.